Furthermore, underlying conditions such as anemia, thyroid issues, or sleep disturbances may exacerbate tiredness
As these medications become among the most widely prescribed in the world, the ability to tailor treatment based on genetic profile or to target specific clinical outcomes such as cardiovascular risk reduction could transform prescribing practices well beyond their current primary use in obesity and diabetes management Sources New 23andMe Research Institute Study Identifies Genetic Predictors for GLP-1 Weight Loss Efficacy and Side Effects 23andME April 8, 2026 Genetic variations linked to weight loss, side effects from GLP-1 drugs Reuters April 10, 2026
For patients with complex health pictures cardiovascular conditions, metabolic disease, diabetes that integration has real clinical value
The primary endpoint will be HbA1c change
Take endocrinologist Karl Nadolsky, D.O